Buy & Sell Kellogg Company (K) – Kellogg Company Price Today
Key Stats
- $29.03BMarket Cap
- Consumer StaplesSector
- -3M Drawdown
- $34.99BEnterprise Value
- 2.78%Dividend Yield
- 107 daysTypical Hold Time
Kellogg Company (K) is currently valued at a market capitalization of $29.03B, with an enterprise value of $34.99B. Over the past 52 weeks, Kellogg Company has traded between a low of $76.96 and a high of $83.64, highlighting its annual price range. Kellogg Company offers a dividend yield of 2.78%, with the most recent dividend of $0.58 paid on 01 Dec 25. On average, investors hold Kellogg Company for approximately 107 days, indicating typical investor behavior on the platform.
About Kellogg Company
Founded in 1906, Kellogg is a leading global manufacturer and marketer of cereal, cookies, crackers, and other packaged foods. Its offerings are manufactured in 21 countries and marketed in more than 180 countries. Its product mix includes well-known brands such as Special K, Frosted Flakes, Froot Loops, Rice Krispies, Pop-Tarts, Eggo, Kashi, and Morningstar Farms. The firm added the Pringles brand to its mix in 2012. Sales outside its home turf account for around 40% of Kellogg's consolidated sales base. The firm intends to split its global snacking arm from its North American cereal and plant-based alternative segments by the end of calendar 2023.
Most Recent News
FTI Consulting hires Jerome Nyssen to boost AI-driven risk and compliance advisory in Australia.
FTI Consulting appointed Jerome Nyssen as Senior Managing Director in its Risk Advisory practice in Australia to enhance AI-driven risk, compliance, and governance services. Nyssen brings 25 years of experience across financial services and technolog...
AI/R advances AI integration in business with Databricks, achieving Gold partner status and boosting client results.
AI/R, a technology company specializing in Agentic AI, has deepened its partnership with Databricks, achieving Gold partner status and expanding its certifications from 11 to over 100. This growth enables AI/R to deliver advanced AI and data solution...
Lebrikizumab sustains atopic dermatitis clearance up to 2 years with less frequent dosing, per new long-term data.
New long-term data from the ADjoin trial shows that lebrikizumab, an injectable treatment for moderate to severe atopic dermatitis, maintains skin clearance and reduces itching for up to 2 years even with monthly dosing instead of biweekly. About 76%...